Navigation Links
First cGMP feeder-independent pluripotent stem cell banks released for distribution

MADISON The WiCell Research Institute and the Waisman Clinical Biomanufacturing Facility (WCBF) announced today (July 6) the release of the first current Good Manufacturing Practices (cGMP) feeder-independent pluripotent stem cell banks available for sale and distribution to researchers worldwide.

These cGMP banks of human embryonic stem (ES) cells are produced using H9 (WA09), one of the original lines derived by stem cell pioneer James Thomson at the University of Wisconsin-Madison and the most frequently used and cited human ES cell line in stem cell research today. Release of this material demonstrates the successful execution of the production, quality-control testing and documentation required for cGMP banks.

Through the new partnership between WiCell and the WCBF, researchers now can purchase matched cGMP and research cell banks, allowing them the opportunity to seamlessly advance their programs from research through clinical application. In the future, WiCell and the WCBF plan to make available a wide variety of other cGMP lines, including lines produced from newly derived, fully compliant human ES cells and induced pluripotent stem (iPS) cells. These clinical-grade cell banks will help advance the field of regenerative medicine.

"The effective development of stem cell-based therapeutics requires cell banks that have been characterized and produced under conditions suitable for human clinical trials," says Thomson, director of regenerative biology at the new private Morgridge Institute for Research at UW-Madison and the scientific director of WiCell. "The availability of these cGMP stem cell banks and matched research cell lines should open the door to more rigorous, reliable and successful clinical applications."

"The availability of stem cell banks that have been produced and tested under cGMP is a critical component of any program that intends to advance a stem cell-based therapy into human clinical trials," says Erik Forsberg, executive director of WiCell. "Using matched research/cGMP stem cell banks early in development will greatly reduce the time and cost associated with transitioning research projects from bench to bedside."

The collaboration between two leading organizations in the stem cell field, the WiCell Research Institute and the Waisman Clinical Biomanufacturing Facility, is key to the successful production of cGMP stem cell products. Human embryonic stem cells cultured and propagated at WiCell serve as the source of the well-characterized research cell banks. Production of clinical master cell banks then is carried out in the WCBF cleanrooms with complete cGMP testing and documentation. Cell banks are offered as research banks derived from the cGMP master cell bank for screening cell properties, as well as cGMP working cell banks, derived from the same fully tested master cell bank under cGMP conditions.

Derek Hei, director of the WCBF, says, "It is a priority of our partnership with WiCell to pursue cGMP feeder-independent production of both human ES and iPS cells. We need to continue work with both cell types until we more thoroughly understand their characteristics and how these characteristics may affect their potential use in therapies."

"cGMP stem cell banks represent the key in today's research market with respect to therapeutics, clinical applications and human clinical trials," says Clive Svendsen, director of Cedars-Sinai Regenerative Medicine Institute, Los Angeles. "For scientists poised to take their research to new levels and explore the reality of using pluripotent stem cells to cure human disease, the tools now provided through this partnership between WiCell and the WCBF signal the beginning of a new era in regenerative medicine."


Contact: Janet L. Kelly
University of Wisconsin-Madison

Related biology news :

1. Which came first, the moth or the cactus?
2. First all-African GM crop is resistant to maize streak virus
3. Scientists retrace evolution with first atomic structure of an ancient protein
4. CU-Boulder team discovers first ancient manioc fields in Americas
5. First finding of a metabolite in 1 sex only
6. First orchid fossil puts showy blooms at some 80 million years old
7. First individual genome sequence published
8. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
9. UNH becomes first university in nation to use landfill gas as primary energy source
10. Scientists in first global study of poison gas in the atmosphere
11. Weight gain between first and second pregnancies associated with increased odds of male second child
Post Your Comments:
(Date:11/9/2015)... , Nov. 09, 2015 ... the addition of the "Global Law ... their offering. --> ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) has ...
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has been ... provide preclinical development services to the National Cancer Institute ... will provide scientific expertise, modern testing and support facilities, ... preclinical pharmacology and toxicology studies to evaluate potential cancer ... The PREVENT Cancer Drug Development Program is an ...
(Date:10/29/2015)... Oct. 29, 2015 Daon, a global leader ... has released a new version of its IdentityX ... North America have already installed IdentityX ... includes a FIDO UAF certified server component ... to activate FIDO features. These customers include some of ...
Breaking Biology News(10 mins):
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: ... adopted a stockholder rights plan (Rights Plan) in an ... loss carryforwards (NOLs) under Section 382 of the Internal ... --> PharmAthene,s use of its NOLs could be ... as defined in Section 382 of the Code. In ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. ... Gorman , President and CEO of Neurocrine Biosciences, will ... Conference in New York . ... visit the website approximately 5 minutes prior to the ... replay of the presentation will be available on the ...
(Date:11/25/2015)... 2015 The Global Genomics ... professional and in-depth study on the current state ... ) , The report ... definitions, classifications, applications and industry chain structure. The ... markets including development trends, competitive landscape analysis, and ...
Breaking Biology Technology: